Seres Therapeutics, Inc. · NASDAQ:MCRB
Seres Therapeutics — Investor Presentation (June 2023)
26 slides from Seres Therapeutics's investor presentation, Jun 28, 2023
Slide 1: Seres Therapeutics June 2023 Corporate Overview
Exhibit 99.1 Seres Therapeutics June 2023 Corporate Overview
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995, including, but not limited to the anticipated supply and degree of market acceptance of VOWST; the potential for microbiome thera
Slide 3: VOWST - First FDA Approved Orally Administered Microbiota-Based Therapeutic
TM VOWST - First FDA Approved Orally Administered Commercially Microbiota-Based Therapeutic available TM VOWST is indicated to prevent the recurrence of C. difficile infection (CDI) in individuals 18 years of age or older following antibacterial treatment for recurrent CDI (rCDI). Seres is pioneerin
Slide 4: Seres Mission: Revolutionary Microbiome Therapeutics
Seres Mission: Transforming the Lives of Patients Worldwide with Revolutionary Microbiome Therapeutics Encapsulated consortia of commensal bacteria designed to target multiple disease-relevant pathways simultaneously Bacterial Consortia Orally-formulated, using current Good Disease Engraftment Restr
Slide 5: Strategic Priorities: Expanding Microbiome Therapeutic Leadership
Strategic Priorities | Expanding Microbiome Therapeutic Leadership FDA approved on April 26, 2023; potential to transform management of recurrent • Successfully commercialize C. difficile infection TM VOWST , first-in-class orally administered microbiome Commercially available • therapeutic • Co-com
Slide 6: VOWST is the First Approval from Our Pipeline of Oral Microbiome Therapeutics
VOWST is the First Approval from Our Pipeline of Oral Microbiome Therapeutics INFECTION PROTECTION Preclinical Phase 1b Phase 2b Phase 3 FDA Approval Collaborators 1,2 VOWST Recurrent C. difficile (fecal microbiota spores, live-brpk) Bloodstream and antimicrobial-resistant bacterial infections & 3 C
Slide 7: VOWST and Recurrent C. difficile Infection
TM VOWST and Recurrent C. difficile Infection 7 Seres Therapeutics, Inc. © 2023
Slide 8: C. difficile Infections Are an Urgent Public Health Threat
C. difficile Infections Are an Urgent Public Health Threat Spore-forming, toxin- Symptoms include colitis Acute onset of severe High probability of producing, gram-positive, and severe, watery symptoms leads to recurrence >20%, usually anaerobic bacteria diarrhea with up to 15 hospitalization for wi
Slide 9: VOWST Offers an Attractive Product Profile
VOWST Offers an Attractive Product Profile Highlights of Prescribing Information Broad product label covering adults with rCDI, including at Indication VOWST is indicated to prevent the recurrence of ✔ first recurrence statement Clostridioides difficile infection (CDI) in individuals 18 years of age
Slide 10: VOWST is Highly Anticipated by Healthcare Professionals
VOWST is Highly Anticipated by Healthcare Professionals TM HCP Intent to Prescribe VOWST Recurrent C. difficile infection is a highly “ debilitating and life-threatening disease, and 22% antibiotics alone do not address the underlying Definitely will cause of rCDI, dysbiosis of the gut microbiome. ~
Slide 11: HCP Enthusiasm for VOWST Driven by Desire to Prevent Recurrences
HCP Enthusiasm for VOWST Driven by Desire to Prevent Recurrences and Limitations of Current Options Top 5 rCDI Treatment Goals Top 5 Unmet Needs % Ranked in Top 3 % Ranked in Top 3 Prevention of Preventing subsequent 59% 66% • Prevention of recurrences is recurrences recurrences seen as a top treatm
Slide 12: Co-commercializing VOWST in the United States with 50/50 Profit Sharing
Co-commercializing VOWST in the United States with 50/50 profit sharing per July 2021 agreement, extending global strategic collaboration Combined Field Teams to Cover Highest Potential rCDI Prescribers Prioritize top volume and early adopting HCPs: Prioritize ~300 top HCOs: 20-person hospital team
Slide 13: Engaging with Key Commercial and Medicare Part D Plans
Engaging with Key Commercial and Medicare Part D Plans to Initiate Broad Coverage Path to coverage for VOWST Payer mix Up to Launch + 12 months Launch + 18 months Payers utilize NTMBs* to limit Medicare coverage 37% Medicare demand begins 54% Commercial Launch + 12 months 6% Medicaid VOWST Medicaid
Slide 14: VOWST Delivers Compelling Value Proposition
VOWST Delivers Compelling Value Proposition We Are Committed to Broad Patient Access Uniquely addresses #1 unmet need of preventing Addresses costly burden of rCDI: $43,000 cost / 1 recurrence, with robust efficacy, an established patient safety profile, and an orally administered regimen Innovative
Slide 15: Laying the Foundations to Ultimately Transform Standard of Care
Laying the Foundations to Ultimately Transform Standard of Care Initial Focus Expanded Focus • Increase HCP awareness and • Drive repeat use among higher- trial of an entirely new modality volume HCPs • Provide positive experience • Increase reach to lower-volume HCPs • Enhance hospital outflow • Op
Slide 16: Well Positioned to Supply Commercial Demand at Launch and Beyond
Well Positioned to Supply Commercial Demand at Launch and Beyond 10+ years of Seres technology & facility investment for anaerobic bacterial therapeutics Seres in-house GMP Manufacturing and Quality Control High-quality CMO support TM VOWST commercial supply + Bacthera collaboration provides redunda
Slide 17: SER-155 and Infection Protection Franchise
SER-155 and Infection Protection Franchise 17 Seres Therapeutics, Inc. © 2023
Slide 18: Antimicrobial Resistant Infections - Urgent Public Health Threat
Antimicrobial Resistant Infections - Urgent Public Health Threat Major burden to society Many high-risk patient populations Declared “one of the • Allogeneic HSCT recipients at risk for world’s most urgent bloodstream infections threats” • Additional patients with suppressed immune systems (e.g., tr
Slide 19: SER-155 Designed to Modulate Targets of Mortality Following Allogeneic HSCT
SER-155 Designed to Modulate Targets that Address Leading Causes of Mortality Following Allogeneic HSCT (allo-HSCT) Investigational 16-strain cultivated bacterial Specifically designed to reduce infections and consortium optimized using MbTx platform GvHD in allo-HSCT recipients Organ Second failure
Slide 20: SER-155 May Represent a Novel Solution to Reduce GI Pathogen Abundance
SER-155 May Represent a Novel Solution to Reduce GI Pathogen Abundance and Infection & GvHD in Allogeneic HSCT • Oral, cultivated consortium, designed to reduce abundance of pathogens linked to infections and GvHD in allogeneic HSCT recipients* Enrollment ongoing in • SER-155 Phase 1b study Cohort 1
Slide 21: ESKAPE Pathogen Domination was Rare and Transient in Cohort 1
ESKAPE Pathogen Domination was Rare and Transient in Cohort 1 ESKAPE pathogen domination* in SER-155 administered subjects observed at rates substantially lower than reference cohort SER-155 Cohort 1 Fig.1 Cumulative Domination Incidence • From HSCT Day 0-30, 11% of patients (1 subject, Fig.1 blue l
Slide 22: SER-155 Potential Integration into Allogeneic HSCT Treatment Regimen
SER-155 Potential Integration into Allogeneic HSCT Treatment Regimen Unique potential clinical and economic value for allogeneic HSCT patients Substantial impact for patients: Favorable safety profile based on almost 30,000 transplants / year across Cohort 1 data suggests appropriate for US and Euro
Slide 23: Seres' Path Forward
Seres’ Path Forward 23 Seres Therapeutics, Inc. © 2023
Slide 24: Maximizing the Opportunity in Infection Protection
Maximizing the Opportunity in Infection Protection Broadly Target Antimicrobial Resistant • Broad preclinical Additional Opportunities Infections portfolio • Driving to an additional clinical development program in 2023 Autologous HSCT • Potentially 2+ Cancer Neutropenia Pre-clinical Portfolio addit
Slide 25: Well Positioned to Commercialize VOWST and Advance Infection Protection Franchise
Well Positioned to Commercialize VOWST and Advance Infection Protection Franchise, Including SER-155 $125 million milestone 3/31/2023 cash balance: received following VOWST $106.5 million approval Secured up to $250 million debt facility; $110 million 3/31/2023 pro-forma cash balance: 1 funded at cl
Slide 26: Continued Microbiome Therapeutic Leadership and Value Creation
Continued Microbiome Therapeutic Leadership, Anticipated Compelling Growth and Value Creation 2023 2025 TM • VOWST transforming standard of care for a TM VOWST approved; broad population of rCDI patients commercialization underway in rCDI • SER-155 in late-stage clinical development • 2+ additional
Seres Therapeutics — Investor Presentation (June 2023) on 6ix